Press release
Gout Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma, Hinova pharma, Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechno
"Gout Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.
The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Gout Pipeline Report: https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years.
• Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others, are developing therapies for the Gout treatment
• Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others are expected to have a significant impact on the Gout market in the coming years.
• In March 2025, Arthrosi Therapeutics, Inc., a late-stage biotech company advancing a next-generation URAT1 inhibitor designed to significantly lower serum urate (sUA) levels, reduce gout flares, and dissolve tophi in patients with gout and tophaceous gout, has announced the first patient has been dosed in REDUCE 1, its second pivotal Phase 3 clinical trial assessing the investigational therapy AR882.
• In June 2024, Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a highly potent and selective next-generation URAT1 inhibitor designed to lower serum urate levels, reduce flares, and address Tophi in gout patients, announced today the dosing of the first patient in REDUCE 2, a pivotal Phase 3 clinical trial aimed at assessing the reduction of sUA levels in individuals with gout.
• In February 2024, PK Med, a biotechnology company headquartered in France, has obtained clearance from the US Food and Drug Administration (FDA) to progress its injectable gout treatment, PKM-01, directly into Phase II clinical trials, bypassing Phase I studies. The Phase II trial will assess three different doses of PKM-01, a combination therapy consisting of controlled-release colchicine with ropivacaine, an anesthetic. This prospective, randomized study aims to determine the optimal dosage of the treatment for further advancement into Phase III trials.
• In March 2023, Selecta Biosciences, Inc. revealed favorable outcomes from the Phase 3 DISSOLVE I & II trials, comparing SEL-212 against a placebo. SEL-212 aims to address chronic refractory gout.
Gout Overview
Gout is a type of inflammatory arthritis caused by the buildup of uric acid crystals in the joints. It typically affects the big toe, but can also occur in other joints like the ankles, knees, or wrists. Gout attacks come on suddenly and cause intense pain, swelling, redness, and warmth in the affected joint. High levels of uric acid in the blood-often due to diet, genetics, or kidney issues-trigger the condition. Treatment includes anti-inflammatory medications, uric acid-lowering drugs, and lifestyle changes such as reducing red meat, alcohol, and sugary drinks. Early treatment can help prevent recurrent attacks and joint damage.
Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Gout Drugs Under Different Phases of Clinical Development Include:
• TJC-0434: TaiwanJ Pharmaceuticals
• NC-2700: Nippon Chemiphar
• Research Program: HemoShear Horizon Therapeutics plc
• NC-2500: Nippon Chemiphar
• PRX-115: Protalix BioTherapeutics
• HZN-457: Horizon Therapeutics plc
• AR-882: Arthrosi Therapeutics
• DYV700: Dyve Biosciences
• LC350189: LG Chem
• SHR-4640: Jiangsu Hengrui Medicine Co.
• SEL-212: Selecta Biosciences Inc
• D-0120 + Allopurinol: InventisBio Co., Ltd
• ALLN-346: Allena Pharmaceuticals
• Dapansutrile: Olatec Therapeutics LLC
• SAP001: Shanton Pharma Co., Ltd.
• Tigulixostat: LG Chem
Gout Route of Administration
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Gout Molecule Type
Gout Products have been categorized under various Molecule types, such as
• Protein
• Small interfering RNA
• Small molecule
• Product Type
Gout Pipeline Therapeutics Assessment
• Gout Assessment by Product Type
• Gout By Stage and Product Type
• Gout Assessment by Route of Administration
• Gout By Stage and Route of Administration
• Gout Assessment by Molecule Type
• Gout by Stage and Molecule Type
DelveInsight's Gout Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Gout Therapeutics Market include:
Key companies developing therapies for Gout are - Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.
Gout Pipeline Analysis:
The Gout pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
• Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Gout drugs and therapies
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gout Pipeline Market Drivers
• The rise in the prevalence of Gout, Novel urate-lowering agents are some of the important factors that are fueling the Gout Market.
Gout Pipeline Market Barriers
• However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.
Scope of Gout Pipeline Drug Insight
• Coverage: Global
• Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others
• Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others
• Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies
• Gout Market Dynamics: Gout market drivers and Gout market barriers
Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Gout Report Introduction
2. Gout Executive Summary
3. Gout Overview
4. Gout- Analytical Perspective In-depth Commercial Assessment
5. Gout Pipeline Therapeutics
6. Gout Late Stage Products (Phase II/III)
7. Gout Mid Stage Products (Phase II)
8. Gout Early Stage Products (Phase I)
9. Gout Preclinical Stage Products
10. Gout Therapeutics Assessment
11. Gout Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gout Key Companies
14. Gout Key Products
15. Gout Unmet Needs
16 . Gout Market Drivers and Barriers
17. Gout Future Perspectives and Conclusion
18. Gout Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Gout Market https://www.delveinsight.com/report-store/gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gout Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Latest Reports:
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma, Hinova pharma, Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechno here
News-ID: 4103543 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
